Skip to main content
 

GEN News: Guide RNA Gears of the CRISPR/Cas9 Machine Detailed

October 22, 2014

Although the CRISPR/Cas9 gene editing system is in wide use, its molecular basis still needs to be better understood. Of particular interest are molecular details that could account for the interactions between Cas9 and guide RNAs.

NPR: In Hopes of Fixing Faulty Genes, One Scientist Starts With the Basics

October 13, 2014

Whether they admit it or not, many (if not most) scientists secretly hope to get a call in October informing them they've won a Nobel Prize. But I've talked to a lot of Nobel laureates, and they are unanimous on one point: None of them pursued a research topic with the intention of winning the prize.

KQED: Janet Napolitano Hopes UC Can Cash In on Companies, Not Just Research

August 7, 2014

When Google went public, Stanford University made millions. The windfall came because Stanford had equity: not only Google’s intellectual property but also the company itself. This kind of direct investment in a startup was not allowed at the University of California — that is, until now.

PR Newswire: Jennifer Doudna, Ph.D., and Emmanuelle Charpentier, Ph.D., Win 2014 Dr. Paul Janssen Award for Biomedical Research

June 24, 2014

Their collaboration led to the discovery of a new method for precisely manipulating genetic information in ways that should produce new insights in health and disease, and may lead to the discovery of new targets for drug development.

Forbes: Gene Therapy's Big Comeback

March 26, 2014

Elliott Sigal earned a reputation at Bristol-Myers Squibb as one of the drug industry’s best research chiefs. His bets on risky technologies like cancer immunotherapy and new types of diabetes drugs helped Bristol turn from a laggard into a growth stock. But there was one technology he wouldn’t touch: gene therapy, which tries to use engineered viruses to defeat disease at the DNA level.

Pages